News
Novo hits back at rivals with cut-price Wegovy subscriptions
Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
News
Biogen swoops on Apellis with $5.6bn offer
In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.
News
UCB brings first therapy for rare disease TK2d to EU
The EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
Sales & Marketing
Commercial teams are running yesterday's plays. AI just chan...
What leading companies are building now is fundamentally different: decision systems.
News
Amgen's BiTE for lung cancer backed for EU approval
Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
